Camlipixant in refractory chronic cough: A Phase 2a, randomized, controlled trial (RELIEF)

This multicenter, randomized, double-blind, placebo-controlled, Phase 2a crossover trial examined the safety and efficacy of escalating doses of camlipixant in 67 patients with refractory chronic cough. The primary efficacy endpoint was placebo-adjusted change from baseline in awake cough frequency at each dose, which was measured using the Vitalograph VitaloJAK cough monitor.